Dermavant Sciences
United States
52 articles with Dermavant Sciences
-
It was a busy week for clinical trial news. Here’s a look.
-
Dermavant to Present New Data on Phase 3 PSOARING Program at 30th EADV Virtual Congress
9/23/2021
Dermavant Sciences will present data from its Phase 3 PSOARING long-term extension study at the 30th European Academy of Dermatology and Venerology (EADV) Virtual Congress, to be held September 29 through October 2, 2021.
-
Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis
9/9/2021
Dermavant Sciences today announced that the first patient has been dosed in a Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD).
-
Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
8/10/2021
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients.
-
Dermavant Announces $200 Million of Financing
6/7/2021
Dermavant to Receive $160 Million from Revenue Interest Sale Upon FDA Approval of Tapinarof, Participants Include Marathon Asset Management and NovaQuest Capital Management
-
Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
6/3/2021
Dermavant Sciences, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer
5/6/2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021
4/23/2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience
-
Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021
4/16/2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant’s two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting
-
FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma™
3/25/2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced the company has been selected to the Fortune 2021 list of Best Workplaces in Health Care & Biopharma™.
-
Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference
3/11/2021
Dermavant Sciences announced that an abstract containing interim analysis data from Dermavant’s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.
-
Its potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
-
Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For”
11/17/2020
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced the company has made its debut on Fortune’s list of “100 Best Small and Medium Companies to Work For.”
-
Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected as Late-Breaking Oral Presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress
10/27/2020
Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected as Late-Breaking Oral Presentation at the 29 th European Academy of Dermatology and Venereology (EADV) Virtual Congress - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 18 Clinical Trials of Tapinarof – - New Drug Application Filing Anticipated in 20
-
Dermavant Announces Presentation of Tapinarof Pivotal Phase 3 PSOARING Data at Fall Clinical Dermatology Conference
10/22/2020
- A Poster on the MUPK Study for Tapinarof Also to be Presented - - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 18 Clinical Trials of Tapinarof - - New Drug Application Filing Anticipated in 2021 -
-
Clinical Catch-Up: August 24-28
8/31/2020
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look. -
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
-
Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis
8/26/2020
- Primary Endpoints Met in PSOARING 1 and PSOARING 2 Clinical Trials (P-values <0.0001) - - Up to 80% of Patients Achieved ≥1-Grade Improvement in PGA - - All Secondary Endpoints Achieved in Both Trials, Including PASI75 - - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 17 Clinical Trials of Tapinarof